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Peptide T is currently in phase II clinical trials for the treatment of AIDS-associated dementia. Its putative mode of action is inhibition of binding 
of the HIV envelope protein (gp120) to its cellular receptor (CD4), thus preventing viral infectivity and gpl20-induced neuronal toxicity. However, 
a number of reports have appeared in the literature which have failed to observe any inhibitory activity of Peptide T on CD4-gp120 binding, thus 
casting doubt on this hypothesis. This study uses a novel biosensor technique to demonstrate that Peptide T does bind to CD4 and that this binding 
can be specificahy inhibited by an anti-CD4 monoclonal antibody. A detailed analysis of the kinetics of the interaction is presented. 
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1. INTRODUCTION 
Peptide T (D-ala’-STTTNYT amide) is currently in 
phase II clinical trials for treatment of AIDS-associated 
neurocognitive impairment [ 11. 
The peptide was originally derived from an octapep- 
tide sequence (ASTTTNYT) of the envelope glycopro- 
tein (gp120) of the ARV2 isolate of HIV and was shown 
by Pert et al. to be a potent inhibitor of [‘z51]gp120 
binding to T4 on rat brain membranes (121. Furthermore, 
HIV infection of human T cells was antagonized by low 
(0.1 nM) concentrations of the peptide [2]. 
Pert and co-workers also noted a sequence similarity 
between peptide T and vasoactive intestinal peptide 
(VIP: residues 7-l 1), and have shown that both peptides 
are potent agonists of human monocyte chemotaxis. 
This interaction is specifically inhibited by anti-CD4 
monoclonal antibodies (MAbs) but not other mononu- 
clear cell MAbs, leading Pert to suggest hat VIP may 
be the endogenous neuropeptide for the CD4 receptor 
[3]. In support of this hypothesis, it was demonstrated 
that tritiated Peptide T binding to rat brain membranes 
can be inhibited by both gp120 and VIP [4]_ 
induced neuronal cell death, but have also shown that 
it can be specifically prevented by anti-CD4 monoclonal 
antibodies, VIP, Peptide T and related Peptide T struc- 
tures from various HIV isolates [6,7]. Pert et al. ex- 
plained the above findings by suggesting that the T4 
receptor found in human brain is normally modulated 
by VIP and that HIV, or more precisely the envelope 
glycoprotein of HIV, mimics VIP binding via peptide T 
(48), a ~nta~ptide found in approximately the same 
region of all sequenced HIV isolates. AIDS-associated 
dementia then results from the interference of gpl20 
with normal VIP-ergic neurotrophic effects and effects 
on cerebral blood flow [S]. 
This relationship between Peptide T, VIP, CD4 and 
gpl20 is consistent with the observed therapeutic bene- 
fits of Peptide T in the treatment of AIDS-associated 
dementia, which appears to result less from viral infec- 
tion than from a direct neurotoxic action of gp120 itself 
[5]. Thus, Pert et al. have not only demonstrated gpl20- 
Despite this impressive array of evidence, Pert’s hy- 
pothesis has been under continuous attack since 1987 
when a number of investigators reported their inability 
to demonstrate any anti-HIV effects of Peptide T under 
various experimental conditions [9,10]. In support of 
Pert, others claim to have confirmed the original work 
[I 1] and a possible explanation has been advanced to 
account for the contradictory findings [12]. The potent 
chemotactic activity of peptide T and related analogs in 
human monocytes has also been confirmed in other 
laboratories [13,14]. Most damning of all, however, is 
a recently published paper [ 151 which asserts categori- 
cally that Peptide T does not bind to CD4. 
Thus, despite the favorable outlook for Peptide T in 
AIDS therapy, the controversy over its mode of action 
remains unresolved. 
*Corresponding author. Fax: (61) (7) 365 1990. 
Abbreviations: VIP, vasoactive intestinal peptide; SPR, surface plas- 
mon resonance; BIA, biospeeific interaction analysis; RU, response 
units; sCD4, soluble CD4. 
In this paper we address the following: 
1. Reinvestigate the binding of Peptide T to CD4, using 
the newly developed detection phenomenon of sur- 
face plasmon resonance (SPR) [l&l 81; 
2. Demonstrate that Peptide T unquestionably does 
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bind to CD4 and that this binding can be specifically 
inhibited by an anti-CD4 monoclonal antibody; 
3. Offer explanations for the failure of other’s to con- 
firm Pert’s observations, and some guidelines for 
avoiding similar pitfalls in the future. 
2. MATERIALS AND METHODS 
2.1. Surface plasmon resonance 
The phenomenon of surface plasmon resonance [191 enables moni- 
toring of macromolecular interactions in real time. The biosensor 
employed in this study (Pha~acia BIAcore) uses a sensor chip com- 
prising a glass slide coated with a thin film of gold. Light is focussed 
on the gold surface of the sensor chip in a wedge shaped beam giving 
a fixed range of incident angles. Above a certain critical angle of 
incidence, total internal reflection is observed. Under these conditions, 
an electromagnetic field component ermed the evanescent wave pen- 
etrates a short distance into the medium oflower refractive index. This 
wave is amplified by resonant oscillation of delocalized electrons (or 
plasmons) in the metal film. This phenomenon is termed surface plas- 
mon resonance. At a specific incident angle, which is dependent on the 
refractive indices of the media, a sharp dip in the intensity of reflected 
light appears. The angle at which this occurs is known as the SPR 
angle. 
In BIAcore, the sensor chip forms one wall of a thin layer flow cell. 
As the refractive index of the solution in contact with the surface 
changes, the displacement of the SPR angle is recorded in real time 
as a sensorgram, and is quantified as response units, RU. The gold film 
on the sensor chip surface in contact with the Aow path is covered with 
a carbox~ethylat~ dextran hydrogel, to which biomolecules can be 
coupled using standard coupling chemistry. Thus one component (li- 
gand) of the interaction is immobilised on the surface. The other 
component (analyte) is allowed to flow over the sensor surface in 
solution. The change in SPR angle is directly related to the change in 
surface concentration of analyte. A response of 1000 RU corresponds 
to a shift of 0.1” in the resonance angle, which in turn represents a 
change in surface protein concentration of about I @mm* or in bulk 
refractive index of about lo-” [20]. 
2.2. Instrumentation and reagents 
The BIAcore system and reagents including sensor chips CM5, 
surfactant P20 and the amine coupling kit containing N-hydroxysuc- 
cinimide (NHS), N-ethyl-K-(3-diethylaminopropyl) carbodiimide 
(EDC) and ethanolamine hydrochloride were obtained from Pharma- 
cia Biosensor AB, Uppsala, Sweden. Human sCD4 was obtained from 
Du Pont, E.I. DuPont de Nemours, Medical Products Dept, Boston, 
USA. T4 monoclonal antibody (SFCH2T4Dll) was obtained from 
Coulter Immunolo~, Hialeah, FL, USA. Peptide T and VIP (residues 
5512) were gifts from Auspep Pty. Ltd., West Melbourne, Australia 
(homogeneity was verified by HPLC and mass spectrometry). The 
buffer used for all experiments was HBS (10 mM HEPES, 3.4 mM 
EDTA, 150 mM NaCl, 0.05% surfactant P20, pH 7.4). 
2.3. ~rnrnob~l~sal~on of ligands onto sensor surfaces 
Immobilisation of ligands (sCD4 or Peptide T) was performed as 
follows, After equilibration with HBS, the automatic robotics injec- 
tion unit incorporated into the BIAcore instrument was programmed 
to perform the following injections. 
(i) Equal volumes of NHS (70 pt. 0.1 M in water) and EDC (70 ~1, 
0.1 M in water) were first mixed by the robot after which 35 ~1 
was injected across the surface to activate the carboxymethylated 
dextran surface. 
(ii) Ligand (50 ,ul, 100 &ml Peptide T in 10 mM sodium acetate, pH 
4.5, or 50 ~1, 30 &ml sCD4 in 10 mM sodium acetate, pH 4.5) 
was then injected across the activated surface. 
(iii) Residual NHS esters were inactivated with ethanolamine (35 ,ffl, 
1 M in water, pH 8.5). 
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(iv) Noncovalently bound ligand was then washed from the surface 
by injecting hydrochloric acid (10 @I, 0.1 M). 
The immobilisation protocol was performed with a continuous flow 
of HBS of 4 @/min. A representative s nsorgram obtained during the 
immobilisation of peptide T is shown in Fig. 1. 
2.4. Binding assays and data analysis 
Each binding cycle was performed with a constant flow of HBS of 
2 @/min. Samples of analyte, prepared in HBS, were injected across 
the surface via a sample loop contained within the fluidics cartridge 
of the system. Once the sample injection was complete, the surface was 
regenerated by injection of 10 mM HCl. Analyte binding was meas- 
ured as the increase in the SPR signal of the immobilised ligand layer 
with HBS flow before and after injection of analyte. Inhibition studies 
were carried out by co-incubating the inhibitor with analyte for 30 min 
at room temperature prior to injection. 
2.5. Theory of kinetic measurements 
To apply the general rate equation 121,221 to the formation of AB 
complexes, the progress of the reaction must be monitored. This is 
usually achieved by determination of the concentration of the complex 
or either of the reactants at known times. For example, the concentra- 
tion of reactant B is given by: 
IBI, = [BIB], - IAB], 
where [B10 is the initial concentration of reactant B at time 0. 
Substitution in to the general rate equation for the formation of 
complex AB yields: 
In real-time biospecific interaction analysis (BIA), complex formation 
is monitored directly as the change in response (R) with time. The 
concentration of free analyte is kept constant through a continuous 
flow of fresh analyte solution past the sensor surface. Denoting the 
analyte as A (concentration C) and the ligand as B gives 
T = k,,, C (&a, - R,) - kdiss R, (Eqn. 1) 
where C is the concentration of free analyte in solution; R,,, is the 
total amount of binding sites of the immobilised Iigand B expressed 
as SPR response in RU; R,,, - R, is the amount of remaining free 
binding sites at time t expressed as SPR response in RU; dR/dt is the 
rate of formation of surface complexes expresses as SPR response in 
RU . se’, i.e. the derivative of the response curve. 
2.5.1. Association 
Rearrangement of the above equation clearly shows that the deriv- 
ative of the binding curve is linearly related to the response. Thus rate 
constants can be derived from a plot of dR/dt versus R: 
dR 
- = k,, C R,,, - (k,,, C + kdas) R, dt (Eqn. 2) 
The problem with this approach is that one needs to know R,,,, the 
response obtained for saturation of the immobilised ligand. This can, 
in principle, be determined by injecting a saturating concentration of 
analyte. However, this requires very high analyte concentrations and 
is thus unrealistic if precious samples are involved. 
Examination of Eqn. 2 reveals that the slope (k,,, C + kdiJ of the 
line obtained by plotting dR/dt against R is itself linearly related to 
the concentration of free andyte C. Hence a plot of the slopes of the 
dR/dt VS. R lines as a function of analyte concentration C, yields a new 
line with slope k,,, and intercept on the abscissa kdlrr, 
2.5.2. Dissociation 
After the sample pulse is complete, the concentration of free analyte 
suddenly drops to zero. The derivative of the response curve then 
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reflects the dissociation rate, assuming that re-association of released 
analyte is negligible: 
Integrating with respect o times gives: 
% 
ln F = .&~ tt, - 2,) 
‘” 
(Bon. 4) 
where R,, is the response at time n and Ru is the response at an 
arbitrary starting time 2,. The dissociation rate constant kdiss can thus 
be obtained by plotting the log of drop in response against time 
interval. 
2.6. Kinerics runs 
sCD4 at concentrations ranging from 10 @ml to 60 &ml in HBS 
was allowed to interact with Peptide T immobilised on the sensor 
surface. The runs were performed at 25°C at a flow rate of 2 @min 
during 25 min (50 ~1 injection), taking report points every 20 s. The 
complex was then allowed to dissociate for 1200 susing a continuous 
flow of buffer at a rate of 2 @/min. Report points were taken every 
50 s. The surface was regenerated with 10 mM HCl over 2.5 min (flow 
rate 50 ,&min). The BIAcore software produces a report point table 
which can be analysed directly in Microsoft Excel. 
3. RESULTS AND DISCUSSION 
3.1. Ligand immobilisation 
Fig. 1 illustrates the immobilisation of Peptide T onto 
the sensor surface. The 639 RU difference between re- 
port points 1 and 2 corresponds to immobilised peptide, 
and is equivalent o a surface concentration of approxi- 
mately 0.6 ng/mm2 [23]. A similar sensorgram was ob- 
tained for the i~obilisation of sCD4 (50 @,35 ,@nl, 
other conditions as stated for peptide T immobilisation) 
with 6973 RU of ligand being immobilised. The greater 
response is due, in part, to the larger molecular weight 
of sCD4 (apparent molecular weight 45.000 Da) as 
compared with Peptide T (858 Da). 
Peptide Immobilization 
0 500 1000 1500 2000 2500 
Time (81 
Fig. 1. ~sorg~rn obtained for the immobilisation of Peptide T. The 
flow rate is 4@min. The beginning and end of injections are indicated 
by arrows. The large differences in RU at the beginning and end of 
injections are due to differences in the refractive indices of the injected 
material and the buffer. The injections performed are (A) activation 
of the carboxylated extran matrix by injection of 35 ~1 of EDCMHS 
mixture, (b) injection of 50 ,uI of 100 &ml of Peptide T in sodium 
acetate, pH 4.5, (C) inactivation of unreacted esters by ethanolamine, 
(D) washing off noncovalently bound peptide with 50 ~1 of IO mM 
Fig. 3. (a) Sensorgram obtained for binding of T4 MAb (50 ~1,0.125 
.&ml) to immobilised sCD4. Flow rate = 2 @min. (b) Sensorgram 
obtained for binding of T4 MAb (50 ~1, 0.125 &ml) to immobilised 
sCD4, after co-incubation with Peptide T (1 mg/ml) for 30 min at room 
HCl. temperature. Flow rate = 2 @/min. 
1 0 700 1400 2100 2800 
Time [sl 
Fig. 2. Sensorgram illustrating binding of Peptide T (50 pl, 10 ,ug/ml) 
to immobilised sCD4, at a flow rate of 2 pl/min. Amount of analyte 
bound is determined by the difference in response before and after the 
injection, i.e. 382 RU. 
3.2. Peptide and monoclonal antibody binding to immo- 
bilised sCD4 
Fig. 2 shows a representative sensorgram obtained 
upon injection of Peptide T (50 ~1, 10 mg/ml) across the 
i~obilised sCD4 surface. The amount of analyte 
bound is measured as the difference between response 
before and after the injection, i.e. between report points 
1 and 2. In this case, a total of 382 RU was obtained. 
A similar response was observed for the VIP fragment 
(residues 5-12, 50 ~1, 10 mg/ml), with a total increase 
of 372 RU. This indicates that both Peptide T and the 
VIP fragment bind to CD4. 
The specificity of this interaction was demonstrated 
by inhibition of the binding of the anti-CD4 monoclonal 
antibody, T4 (50,&,0.125 pg/ml), to i~obilised sCD4 
(Fig. 3a). This was completely inhibited by pre-incuba- 
tion with Peptide T (1 mg/ml) (Fig. 3b), suggesting that 
Peptide T binds to sCD4 at the same site as the mono- 
cfonal antibody T4. 
3.3. sCD4 binding to immobilisedpeptide T 
Fig. 4 shows representative sensorgrams of the bind- 
ing of sCD4 (10, 21, 35, 60 &ml) to immobilised Pep- 
tide T. The amount of analyte bound to the surface was 
100, 152, 207, 247 RU for 10, 21, 35 and 60 ,&nl 
concentrations of sCD4, respectively. 
Fig. 5 shows the corresponding sensorgram of the 
binding of sCD4 (10 puglml) after incubation with T4 
monoclonal antibody (0.125 pg/ml). The response is 
j 3550 3850 4150_ [4s;p50 4750 5050 1 
/ 
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Fig. 4. Sensorgrams obtained for binding of soluble sCD4 to immobilised Peptide T. Flow rate = 2 @min. 50 pl injections of the following 
concentrations were made. Sensorgrams are illustrated in the corresponding panels: (a) 60 &/ml; (b) 35 &ml; (c) 21 @g/ml; (d) 10 ,&nl. 
now greatly reduced, i.e. only 26 RU of analyte bound 
as compared with 100 RU in the absence of T4. This 
indicates that T4 monoclonal antibody inhibits the 
a 
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Fig. 5. (a) Sensorgram obtained upon binding of sCD4 (50 ~1, 10 
@ml) to immobilised Peptide T. Flow rate = 2 @/min. (b) Sen- 
sorgram obtained upon binding of sCD4 (50~1, lO,~g/ml) to immobil- 
ised Peptide T, after co-incubation with T4 MAb for 30 min at room 
temperature. Flow rate = 2 ,ul/min. 
binding of sCD4 to peptide T. As shown earlier (Fig. 3), 
Peptide T was also able to inhibit the binding of this 
MAb to sCD4. Since the T4 monoclonal is known to be 
specific for the gpl20 binding site of sCD4, this indi- 
cates that peptide T also binds to CD4 in this region. 
3.4. Kinetics analysis of sCD4-peptide T interaction 
Plots of dR/dt vs. R for the four different concentra- 
tions (10, 21, 35 and 60 @ml) of sCD4 binding to 
i~obilised peptide T (illustrated in Fig. 4) yielded 
slopes of 0.002224 (r = 0.992), 0.~3029 (r = 0.969}, 
0.004628 (r = 0.986) and 0.007473 (r = 0.979), respec- 
tively (Fig. 6a). Fig. 6b shows a plot of these derived 
slopes versus analyte concentration. The slope of this 
plot yields an apparent association rate constant of 4820 
M-’ . s-’ (r = 0.997). 
Dissociation constants were calculated according to 
Eqn. 4. A representative plot for the dissociation of 
sCD4 (35 yglmi) from immobilised Peptide T is shown 
in Fig. 7. The dissociation plot is not linear, but appears 
to comprise an initial rapid dissociation (kdiss = 
2.3 x 10e4 s-‘), followed by a slower dissociation phase 
(kdiss = 9.5 x lo-’ s-‘). Such phenomena have been 
noted previously and could be expected if the binding 
is multivalent, if the ligand is heterogeneous or if the 
i~obilisation has caused the ligand to appear hetero- 
geneous [24]. Also rebinding of newly dissociated ana- 
lyte is possible, especially if the number of available 
binding sites is high [25]. The initial dissociation rates 
obtained with the 21 @ml and 60 ,@ml injections (Fig. 
4b and d) of sCD4 were comparable, yielding apparent 
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Fig. 6. (a) Slope vs. response for the association phase of sCD4 binding 
to Peptide T, obtained from sensorgrams hown in Fig. 4. Report 
points were taken every 20 s, q , 10 &ml; A, 21 &ml; l , 35 pg/ml; 
l , 60 &ml. (b) Plot of slopes derived from Fig. 6a vs. sCD4 concen- 
tration. 
dissociation constants of 2.6 x 10m4 s-’ and 3.3 x 10m4 
s-l, respectively. Analysis of the dissociation plot shown 
in Fig. 7 revealed that approximately 8% of the ligand 
dissociates at the faster rate, with a further 24% dissoci- 
ating at the slower rate over the remaining time period 
measured. However, it should be noted that the lowest 
concentration of sCD4 (10 &ml, Fig. 4a) failed to 
show any observable dissociation even after 3000 s. This 
is indicative of a dissociation rate of 10m6 s-’ or greater 
WI. 
Using the ratio of the apparent association rate, 4820 
M-’ . s-’ and the measurable dissociation rates, 
2.7 x low4 (average value) and 9.5 x 10e5 s-‘, &‘s of 20 
and 56 nM were obtained. 
4. CONCLUSION 
Using novel biosensor technology, we have demon- 
strated that 
(9 Peptide T does indeed bind to CD4, with an appar- 
ent association rate of 4820 M-l . s-l and two ap- 
parent dissociation rates of 9.5 x lo-’ s-l and 
2.7 x 10m4 s-l, givingC K’s of 20 nM and 56 nM, 
respectively. 
(ii) the binding of peptide T to CD4 can be inhibited 
(iii) 
by the monoclonal antibody T4. This antibody is 
directed to the gp120 binding site of CD4 and is 
known to inhibit the binding of gp120 to CD4. 
Inhibition of peptide T binding by MAb T4 thus 
suggests that peptide T may bind at the same site 
as gp120. 
VIP (residues 5-12) also binds to CD4, apparently 
at the same site. This is of importance as it provides 
a possible mechanism of action for the observed 
neurological benefits of peptide T that have been 
observed in AIDS patients. The data presented 
here suggest that peptide T and VIP (residues 5-12) 
bind to CD4 thus supporting the hypothesis of 
Brenneman et al. that peptide T prevents neuronal 
cell death by inhibiting the binding of neurotoxic 
gp120. 
In summary, our findings support the original hy- 
potheses of Pert and co-workers that Peptide T and the 
VIP fragment (residues 5-12) bind to CD4 with high 
affinity and that this binding can be inhibited by a mon- 
oclonal antibody known to prevent gp120 binding. The 
contradictory reports in the literature may be due, at 
least in part, to labelling of ligands which interfere with 
the interaction under investigation. In particular, the 
most recently published paper refuting the interaction 
of Peptide T and CD4 [15] uses iodinated Peptide T. 
Pert et al. had previously shown that tyrosine-7 of Pep- 
tide T is crucial for activity and that iodination of this 
residue abolished activity [27]. It is interesting to note 
that the only other non-conflicting studies in the litera- 
ture are those involving chemotaxis assays, which do 
not require the use of labelled ligands. However, such 
assays do not allow the detailed analysis of interaction 
kinetics presented here. It is hoped that this study will 
0.35 
0.3 
^ 0.25 
5 
B 0.2 
/ 
/Kd =2.3 e-4 
Fig. 7. Dissociation phase plot illustrating the kinetics of dissociation 
for sCD4 (35 ,~g/ml) from immobilised Peptide T. Apparent dissocia- 
tion constants, Kg were calculated from the slopes of the two lines, 
as indicated. 
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assist to dispel the controversy that has arisen surround- 
ing Peptide T and its mode of action. 
REFERENCES 
[1] AIDS Medicines in Development: Drugs and Vaccines. Phar- 
maeutical Manufacturer’s Association (1991). 
[2] Pert, C.B., Hill, J.M., Ruff, M.R., Berman, R.M., Robey, W.G., 
Arthur, L.O., Ruscetti, F.W. and Farrar, W.L. (1986) Proc. Natl. 
Acad. Sci. USA 83, 92549258. 
[3] Ruff, M.R., Martin, B.M., Ginns, E.I., Farrar, W.L. and Pert, 
C.B. (1987) FEBS Lett. 211, 17-22. 
[4] Smith, CC., Hallberg, P.L., Sacerdote, P., Williams, P., Stern- 
berg, E.M., Martin, B.M., Pert, C.B. and Ruff, M.R. (1988) Drug 
Dev. Res. 15, 371-379. 
[5] Glowa, J.R., Panlilio, L.V., Brenneman, D.E., Gazes, I., Fridkin, 
M. and Hill, J.M. (1992) Brain Res. 570, 49-53. 
[6] Brenneman, D.E., Westbrook, G., Fitzgerald, S.P., Ennist, D.L., 
Elkins, K.L., Ruff, M. and Pert, C.B. (1988) Nature 335,639-642. 
[7] Brenneman, D.E., Buzy, J.M., Ruff, M.R. and Pert, C.B. (1988) 
Drug Dev. Res. 15, 361-369. 
[8] Pert, C.B., Smith, C.C., Ruff, M.R. and Hill, J.M. (1988) Ann. 
Neurol., Supplement to Volume 23, S71-S73. 
[9] Haseltine, W., Sodroski, J., Kowalski, M., Dorfman, T., Basiri- 
pour, L. and Rosen, C. (1987) The Lance& June 20, 142881429. 
[lo] Clumeck, N. and Hermans, P. (1988) Am. J. Med. 85, 165-172. 
[l l] Newmark, P. (1987) Nature, 327, 449. 
[12] Ruff, M.R., Hallberg, P.L., Hill, J.M. and Pert, C.B. (1987) The 
Lancet, September 26, 751. 
[13] Marastoni, M., Salvadori, S., Balboni, G., Spisani, S., Gavioli, 
R., Traniello, S. and Tomatis, R. (1990) Int. J. Peptide Protein 
Res. 35, 81-88. 
[14] Marastoni, M., Salvadori, S., Balboni, G., Scaranari, V., Spisani, 
S., Reali, E., Giuliani, A.L. and Tomatis, R. (1992) Eur. J. Med. 
Chem. 27, 383-393. 
[15] Van den Heever, L.H., Jordaan, J.H. andDubery, IA. (1992) Int. 
J. Biochem. 24, 337-339. 
[16] Malmqvist, M. (1993) Nature 361, 186-187. 
[17] Fagerstam, L. (1991) in: Techniques in Protein Chemistry II, pp. 
65-71, Academic Press, New York. 
[18] Jonsson, U. and Malmqvist, M. (1992) in: Advances in Biosen- 
sors (Turner, A.P.F., Ed.) Vol. 2, pp. 291-336, JAI Press, Lon- 
don. 
[19] Liedberg, B., Nylander, C. and Lundstrom, I. (1983) Sensors 
Actuators 4, 299-304. 
[20] Lofas, S. and Johnsson, B. (1990) J. Chem. Sot., Chem. Com- 
mun. 21, 15261528. 
[21] Azimzedeh, A. and Van Regenmortel, M.H.V. (1990) J. Mol. 
Recog. 3, 108-l 16. 
[22] Altschuh, D., Dubs, M-C., Weiss, E., Zeder-Lutz, G. and Van 
Regenmortel, M.H.V. (1992) Biochemistry 31, 62986304. 
[23] Sterberg, E., Persson, B., Roos, H. and Urbaniczky, C. (1991) J. 
Colloid Interface Sci. 143, 513-526. 
[24] Fagerstam et al. (1992) J. Chromatogr. 597, 397410. 
[25] Felder, S., Zhou, M., Hu, P., Urena, J., Ullrich, A., Chaudhuri, 
M., White, M., Shoelson, S.E. and Schlessinger, J. (1993) Mol. 
Cell Biol. 13, 144991455. 
[26] Borrebaeck, C.A.K., Malmborg, A-C., Furebring, C., 
Michaelson, A., Ward, S. and Ohlin, M. (1992) Biotechnology 10, 
697-698. 
[27] Sacerdote, P., Ruff, M.R. and Pert, C.B. (1987) J. Neurosci. Res. 
18, 1022107. 
222 
